SmartLabs and IWG Announce 10-Year Partnership to Deliver Fully Managed Lab Infrastructure Worldwide
First-of-its-kind collaboration will integrate SmartLabs' turnkey laboratory solutions across IWG's global portfolio of flexible workspace brands
BOSTON and ZUG, Switzerland, June 17, 2025 /PRNewswire/ -- SmartLabs, the leading provider of flexible laboratory infrastructure and resourcing solutions, and International Workplace Group (IWG), the world's largest flexible and hybrid workspace platform with brands including Regus, Spaces, Signature and HQ, today announced a 10-year global partnership to meet growing demand for fully managed lab environments in emerging and established life sciences hubs.
Unveiled during the 2025 BIO International Convention in Boston, this first-of-its-kind collaboration will integrate SmartLabs' high-performance lab solutions into IWG's global portfolio of flexible workspace brands—making it significantly easier for life sciences innovators, institutions, and investors to establish R&D capabilities in new and underserved markets around the world.
Through the partnership, SmartLabs will deliver its comprehensive lab-as-a-service model—including site selection, lab design, construction management, daily operations, and ongoing scientific support to end users—across multiple geographies. Tailored to the needs of each local scientific ecosystem and aligned with the strategic priorities of SmartLabs' and IWG's partners, these capabilities will empower life sciences and emerging technology companies to access world-class, flexible R&D environments, and scale their research seamlessly across the entire innovation lifecycle.
"Many regions around the world are rich in scientific talent and ambition but lack the advanced lab infrastructure and support services needed to move research forward," said Brian Taylor, CEO of SmartLabs. "By combining our scientific and operational expertise with IWG's international reach, we can now deliver fully managed, high-performance R&D environments directly to underserved markets across Europe, Asia, and beyond. Whether it's early-stage biotechs, global pharma, or other life sciences and tech companies, we are here to help them focus their time and resources on what matters most—pushing science forward, faster."
For SmartLabs, the agreement accelerates global expansion, delivering the company's innovative lab solutions more quickly to scientists and research teams where they are needed most. For IWG, it marks an entry into lab-enabled real estate—offering new opportunities for landlords, developers, and capital partners to access the high-growth life sciences and tech sectors with proven, low-risk, turnkey solutions.
"We have seen how IWG's portfolio of flexible workspace brands unlocks significant value for landlords, developers, and local ecosystems across the globe, providing access to the world's largest platform for work operating in more than 120 countries. Through our partnership with SmartLabs, we are bringing that same model to the world of science and innovation," said Mark Dixon, Founder and CEO of IWG. "This new offering gives our partners a powerful opportunity to meet the growing demand for specialized lab environments—without the complexity of building or operating them on their own. Together, we are enabling faster, smarter delivery of research-ready spaces in key innovation markets worldwide."
The announcement comes amid rising global demand for R&D space and increasing pressure on life sciences and technology companies to move quickly while managing capital more efficiently. SmartLabs' fully managed platform helps companies reduce time to operational readiness, streamline day-to-day operations, and stay focused on driving scientific innovation forward.
About SmartLabs
SmartLabs was founded in 2015 based on the belief that modern science requires a new, adaptable resourcing infrastructure as the standard to future-proof the industry and accelerate the pace of scientific breakthroughs for everyone, everywhere. The company offers the first integrated platform combining flexible lab infrastructure, operations, digital solutions, and scientific expertise.
Its Managed Research Centers allow clients to access private, enterprise-grade R&D infrastructure and manufacturing solutions "as-a-service" without upfront capital investments, providing holistic end-to-end solutions for new technology and life sciences companies across all stages of the innovation lifecycle. With headquarters in Boston, SmartLabs serves diverse biotech, pharma, and new technology organizations with a unique model designed to help enable the future of the industry.
For more information, visit www.smartlabs.com.
About International Workplace Group plc
International Workplace Group is the global leader in hybrid work solutions and workspace brands. We create personal, financial, and strategic value for businesses of every size. From some of the most exciting companies and well-known organizations on the planet, to individuals and the next generation of industry leaders. All of them harness the power of International Workplace Group's hybrid working platform to increase their productivity, efficiency, agility, and market proximity.
International Workplace Group's unrivalled network coverage includes more than 4,000 locations across more than 120 countries and 83% of Fortune 500 companies are amongst our growing customer base.
Through our brands including Regus, Spaces, HQ and Signature, we help millions of people and their businesses to work more productively. We do so by providing the world's leading hybrid work platform with professional, inspiring and collaborative workspaces and digital services all available via the International Workplace Group's app.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Korea Herald
6 hours ago
- Korea Herald
SmartLabs and IWG Announce 10-Year Partnership to Deliver Fully Managed Lab Infrastructure Worldwide
First-of-its-kind collaboration will integrate SmartLabs' turnkey laboratory solutions across IWG's global portfolio of flexible workspace brands BOSTON and ZUG, Switzerland, June 17, 2025 /PRNewswire/ -- SmartLabs, the leading provider of flexible laboratory infrastructure and resourcing solutions, and International Workplace Group (IWG), the world's largest flexible and hybrid workspace platform with brands including Regus, Spaces, Signature and HQ, today announced a 10-year global partnership to meet growing demand for fully managed lab environments in emerging and established life sciences hubs. Unveiled during the 2025 BIO International Convention in Boston, this first-of-its-kind collaboration will integrate SmartLabs' high-performance lab solutions into IWG's global portfolio of flexible workspace brands—making it significantly easier for life sciences innovators, institutions, and investors to establish R&D capabilities in new and underserved markets around the world. Through the partnership, SmartLabs will deliver its comprehensive lab-as-a-service model—including site selection, lab design, construction management, daily operations, and ongoing scientific support to end users—across multiple geographies. Tailored to the needs of each local scientific ecosystem and aligned with the strategic priorities of SmartLabs' and IWG's partners, these capabilities will empower life sciences and emerging technology companies to access world-class, flexible R&D environments, and scale their research seamlessly across the entire innovation lifecycle. "Many regions around the world are rich in scientific talent and ambition but lack the advanced lab infrastructure and support services needed to move research forward," said Brian Taylor, CEO of SmartLabs. "By combining our scientific and operational expertise with IWG's international reach, we can now deliver fully managed, high-performance R&D environments directly to underserved markets across Europe, Asia, and beyond. Whether it's early-stage biotechs, global pharma, or other life sciences and tech companies, we are here to help them focus their time and resources on what matters most—pushing science forward, faster." For SmartLabs, the agreement accelerates global expansion, delivering the company's innovative lab solutions more quickly to scientists and research teams where they are needed most. For IWG, it marks an entry into lab-enabled real estate—offering new opportunities for landlords, developers, and capital partners to access the high-growth life sciences and tech sectors with proven, low-risk, turnkey solutions. "We have seen how IWG's portfolio of flexible workspace brands unlocks significant value for landlords, developers, and local ecosystems across the globe, providing access to the world's largest platform for work operating in more than 120 countries. Through our partnership with SmartLabs, we are bringing that same model to the world of science and innovation," said Mark Dixon, Founder and CEO of IWG. "This new offering gives our partners a powerful opportunity to meet the growing demand for specialized lab environments—without the complexity of building or operating them on their own. Together, we are enabling faster, smarter delivery of research-ready spaces in key innovation markets worldwide." The announcement comes amid rising global demand for R&D space and increasing pressure on life sciences and technology companies to move quickly while managing capital more efficiently. SmartLabs' fully managed platform helps companies reduce time to operational readiness, streamline day-to-day operations, and stay focused on driving scientific innovation forward. About SmartLabs SmartLabs was founded in 2015 based on the belief that modern science requires a new, adaptable resourcing infrastructure as the standard to future-proof the industry and accelerate the pace of scientific breakthroughs for everyone, everywhere. The company offers the first integrated platform combining flexible lab infrastructure, operations, digital solutions, and scientific expertise. Its Managed Research Centers allow clients to access private, enterprise-grade R&D infrastructure and manufacturing solutions "as-a-service" without upfront capital investments, providing holistic end-to-end solutions for new technology and life sciences companies across all stages of the innovation lifecycle. With headquarters in Boston, SmartLabs serves diverse biotech, pharma, and new technology organizations with a unique model designed to help enable the future of the industry. For more information, visit About International Workplace Group plc International Workplace Group is the global leader in hybrid work solutions and workspace brands. We create personal, financial, and strategic value for businesses of every size. From some of the most exciting companies and well-known organizations on the planet, to individuals and the next generation of industry leaders. All of them harness the power of International Workplace Group's hybrid working platform to increase their productivity, efficiency, agility, and market proximity. International Workplace Group's unrivalled network coverage includes more than 4,000 locations across more than 120 countries and 83% of Fortune 500 companies are amongst our growing customer base. Through our brands including Regus, Spaces, HQ and Signature, we help millions of people and their businesses to work more productively. We do so by providing the world's leading hybrid work platform with professional, inspiring and collaborative workspaces and digital services all available via the International Workplace Group's app.
![[Bio USA] Korea Bio opens largest national pavilion at Bio USA 2025](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F17%2Fnews-p.v1.20250617.64673f90ba7d43f7bef520f5aa7b8758_T1.jpg&w=3840&q=100)
![[Bio USA] Korea Bio opens largest national pavilion at Bio USA 2025](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75)
Korea Herald
15 hours ago
- Korea Herald
[Bio USA] Korea Bio opens largest national pavilion at Bio USA 2025
BOSTON — The Korea Bio, in collaboration with KOTRA, has showcased the largest national pavilion at this year's BIO International Convention, occupying an expansive 1,800-square-meter space. Featuring booths for 51 companies and organizations, the Korea Pavilion was bustling with company officials engaging with visitors, hosting investor relations sessions and showcasing their innovations on the first day. 'Korea securing the largest exhibition space among all national pavilions is a clear signal that the global market recognizes the potential of Korean biotech,' said Lee Seung-kyu, vice chairman of Korea Bio, during a press briefing at the pavilion on Monday. 'This year's event particularly reflects heightened global market volatility post US presidential election,' Lee said. 'It's not just industry players, but government agencies, regulators and moderators from the regulatory sphere participating as well. The atmosphere underscores how biotech is no longer just a promising sector, but it's becoming a 'strategic asset' for national interests.' The vice president also pointed to the rise of aggressive competitors in the region, including India, Thailand and Indonesia, and most notably Japan, which is stepping up its presence in the global biotech space. 'Fujifilm for instance, which previously focused on chemicals, has now transformed into a full-fledged life science company with a well-established system. They're actively expanding, building new manufacturing facilities in the US," Lee explained. Looking at countries such as Thailand and Indonesia that are ramping up investment in biotech, Lee insisted that Korea must secure a "meaningful position" within the next 'three to five years.' Lee also commented on former US President George W. Bush's scheduled keynote address on Tuesday, saying it reflects how seriously the US regards the biotechnology sector. 'The US is increasingly anxious about being outpaced by countries like China, and from what I hear within the American biotech community, even they are tense about those unpredictable policy changes,' Lee said. With the US government now scrutinizing issues such as inflated drug prices and health insurance premiums, the vice president believes this could benefit the biosimilar sector, and Korean companies may be well-positioned to capitalize on the shift. Lastly, Lee emphasized Korea Bio's commitment to becoming a unifying force for the nation's biotech industry by fostering greater collaboration across institutions to strengthen Korea's position in the global value chain. 'For global big pharma, CDMO capabilities are important, but drug discovery and innovation are also crucial touchpoints. Korean companies have so far made strides as 'fast followers,' but now is the time to become 'first movers,'' he said. 'To support this transition, the new Korean government must also provide policy-level support from a truly global perspective.'


Korea Herald
4 days ago
- Korea Herald
Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD'
SEOUL, South Korea, June 13, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on the 13th that it will participate in the 2025 BIO International Convention (BIO USA), which will be held in Boston, USA from June 16 to 19 (local time). At this year's BIO USA, Neurophet will introduce its software solution, Neurophet AQUA AD, which enables monitoring of prescription, treatment efficacy, and side effects of treatment for Alzheimer's disease. Neurophet AQUA AD provides precise brain imaging analysis throughout the course of anti-amyloid antibody therapy by quantitatively analyzing MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans. Lately, Alzheimer's disease clinical trials have been rising significantly in the biopharmaceutical industry which led to the importance of quantitative brain imaging biomarker analysis. Alzheimer's disease drugs such as Leqembi (lecanemab) and Kisunla (donanemab) require essential monitoring for potential side effects, which Neurophet AQUA AD can provide and meet demand for global expectations. Neurophet will exhibit at the Korea Pavilion, jointly organized by the Korea Biotechnology Industry Organization and the Korea Trade-Investment Promotion Agency (KOTRA), and showcase Neurophet AQUA AD along with its suite of neuroimaging and brain stimulation solutions. It includes Neurophet AQUA, a neurodegeneration imaging analysis software; Neurophet SCALE PET, a PET image quantification software; Neurophet tES LAB, a treatment planning software for brain stimulation; and Neurophet innk, a transcranial electrical stimulation (tES) device. Neurophet plans to strengthen its imaging CRO (Contract Research Organization) business for clinical trials related to Alzheimer's disease treatment through business meetings at this year's BIO USA. The company will also engage in partnering activities with global big pharma and potential clients. Jake Junkil Been, Co-CEO of Neurophet said that "Neurophet AQUA AD has garnered significant interest from both South Korea and global companies in the field of brain imaging-based biomarker development. Through our participation in BIO USA, we aim to accelerate business development collaborations in the imaging CRO sector and further expand into the companion diagnostics market." BIO USA is the world's largest biotechnology exhibition, serving as a global networking hub where stakeholders across the pharmaceutical and biotech industries come together to explore partnership opportunities. This year's event is expected to host over 1,500 companies and more than 20,000 participants from around the world. About Neurophet Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system. Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS". Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.